Key facts
- Notable investors include SBXi, The Engine, MIT Delta V, Solivera Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Continuity (Mountain View)
- ·The full record, as it builds
Funding rounds
No funding rounds for Continuity (Mountain View) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Continuity (Mountain View)
Developer of implantable nanofluidic systems and automated microfluidic devices intended for sustained therapeutic delivery and real-time biological monitoring. The company's platform integrates 3D-printed cell encapsulation technologies with tunable silicon membranes to facilitate zero-order release kinetics, in vivo cell reprogramming, and continuous molecular signal decoding, enabling biopharmaceutical partners and clinical providers to enhance treatment adherence for chronic diseases while maintaining personalized, data-driven oversight of patient health states through high-precision, site-specific administration.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2024
- Employees
- 6
- Website
- continuity.bio/
- Ownership
- Privately Held (backing)
Continuity (Mountain View) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Continuity (Mountain View) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Continuity (Mountain View) in its N-PORT filings yet. We sweep new filings monthly.